Hyperuricemia in female and male patients of chronic plaque psoriasis

Authors

  • Hafiz Bashir Ahmed
  • Farhan Mir
  • Muhammad Suleman Pirzado
  • Ajmal Rashid

DOI:

https://doi.org/10.66344/jpad.27.3.2017.1115

Keywords:

Serum uric acid, chronic plaque psoriasis

Abstract

Objective To determine hyperuricemia in patients with chronic plaque psoriasis. Methods Out of 194, 97 biopsy proven patients of psoriasis were taken as cases and 97 participants coming to OPD with any other skin disease like acne, alopecia, dermatomycosis etc. as controls. 5ml of venous blood was drawn in sterile syringe and using gel sample tube was sent to the laboratory for serum uric acid level. Results There were 54.6% (106/194) male and 45.4% (88/194) female. Patients of psoriasis had hyperuricemia more frequently than controls (25.8% vs. 7.2%). Although male patients and similar frequency of hyperuricemia as in controls (15.2% vs. 6.7%), female patients had significantly more frequent than controls (35.3% vs. 8.1%). Conclusion Hyperuricemia is a common finding in psoriatic patients. Its treatment might be clinically useful for the global treatment of patients. We found a female preponderance which could also be due to the overall more proportion of female patients visiting the clinic. 

References

Burden AD, Kirby B. Psoriasis and related disorders. Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook's Textbook of Dermatology, 9th edition. Oxford: John Wiley & Sons; 2016. P. 35.1-35.48.

Ejaz A, Suhail M, Iftikhar A. Psoriasis in Pakistani population: Associations, comorbidities, and hematological profile. J Pak Assoc Dermatol. 2013;23:42-6.

Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159:10-7.

Ghazizadeh R, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7:284-9.

Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.

Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther. 2014;4:1-9.

Ibrahim SE, Helmi A, Yousef TM, Hassan MS, Farouk N. Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis. Egyptian Rheumatol. 2012;34:83-9.

Kwon H, et al. Crossâ€sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36:473-8.

Lambert JR, Wright V. Serum uric acid levels in psoriatic arthritis. Ann Rheum Dis. 1977;36:264-7.

Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21.

Jain V, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 2011;26:309-11.

Tickner A, Mier P. Serum cholesterol, uric acid and proteins in psoriasis. Br J Dermatol. 1960;72:131-7.

Lea WA, Curtis AC, Bernstein I. Serum uric acid levels in psoriasis. J Invest Dermatol. 1958;31:269-71.

Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038-44.

Murray M, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using sameâ€gender siblings as controls for obesity. Clin Exp Dermatol. 2009;34:140-44.

Downloads

Published

2018-03-15

How to Cite

1.
Ahmed HB, Mir F, Pirzado MS, Rashid A. Hyperuricemia in female and male patients of chronic plaque psoriasis. J Pak Assoc Dermatol [Internet]. 2018Mar.15 [cited 2026Apr.12];27(3):259-62. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1115

Issue

Vol. 27 No. 3 (2017): July - September

Section

Original Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.